Oxide-DFHBI-demethyl is a target aptamer ligand (Ligand for Target Protein for PROTAC). Oxide-DFHBI-demethyl can be used for synthesis of RNA aptamer-based PROTAC Dth.

Oxide-DFHBI-demethyl-C6-NH2 is a Target Protein Ligand-Linker Conjugate that incorporates a target aptamer ligand and a PROTAC linker, which recruits E3 ligases. Oxide-DFHBI-demethyl-C6-NH2 can be used for synthesis of RNA aptamer-based PROTAC Dth

Chlorozotocin (NSC 178248) is a glucose-based chloroethylnitrosourea with low myelotoxicity for studying leukemia in mice.

(+)-Arhalofenate ((+)-MBX 102) is the less active enantiomer of Arhalofenate. Arhalofenate is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.

L-163017 is a potent, orally active and nonpeptide angiotensin II receptor (AT) antagonist. L-163017 can inhibit prevent the pressor response to angiotensin II and reduce blood pressure. L-163017 can be used for the research of cardiovascular disease, such as hypertension.

Ro 17-1812 is a benzodiazepine receptor partial agonist with anticonvulsant effect.

Fmoc-Val-Lys(Boc)-PAB-Exatecan (Compound 39-7) is a Drug-Linker Conjugates for ADC. Fmoc-Val-Lys(Boc)-PAB-Exatecan consists of the ADC Cytotoxin Exatecan and a linker PAB-Val-Lys-Boc. Fmoc-Val-Lys(Boc)-PAB-Exatecan can be used for synthesis of ADCs.

Fmoc-Val-Lys-PAB-Exatecan is a derivative of Exatecan (DX-8951). Fmoc-Val-Lys-PAB-Exatecan can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. Fmoc-Val-Lys-PAB-Exatecan is often combined with CD70 mAb to form ADC drugs for the study of tumors with high CD70 expression.

SB 204144 is an HIV protease inhibitor. SB 204144 can be used in research on immune system diseases.

GR 250495X is an inhaled glucocorticoid receptor agonist. GR 250495X is designed as a antedrug, which takes effect locally in the lungs but is rapidly metabolized and inactivated in the bloodstream after entering the systemic circulation, thereby minimizing systemic side effects. GR 250495X can be used in asthma research.

YM-534, an imidazole compound, is an anti-cancer agent. YM-534 inhibits HL-60 cells with an IC50 of 2.5 μM. YM-534 retards the processing of preribosomal to ribosomal RNA of HL-60 cells. YM-534 can be used for the study of promyelocytic leukemia.

CGP 43487 is a NMDA receptor antagonist. CGP 43487 significantly affects the gross structural characteristics of the developing dentate gyrus.

RP-60503 is an orally active anxiolytic cyclopyrrolone derivative with low sedative potential. RP-60503 binds to the gamma-aminobutyric acidA (GABA)/benzodiazepine receptor with a Ki value of 1.16 nM. RP-60503 can be used for the research of neurological disease.

Hedgehog IN-11 is an orally active Hedgehog inhibitor. Hedgehog IN-11 downregulates the expression of O6-methylguanine-DNA methyltransferase (MGMT) to impair the Temozolomide (TMZ) resistance by inhibiting the Hedgehog pathway. Hedgehog IN-11 shows improved inhibition of cell migration and invasion, and induced cell apoptosis in TMZ-resistant GBM cell lines. Hedgehog IN-11 is predicted by computer simulation to have good blood-brain barrier penetration. Hedgehog IN-11 can be used for the study of glioblastoma (GBM).

Bispiperidin-piperazin-acetate is a PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC RIPK1 Degrader-1.

Boc-Dipiperidine-KLHDC2 ligand 1 is an E3 ligase ligand-linker conjugate that incorporates a KLHDC2 ligand. Boc-Dipiperidine-KLHDC2 ligand 1 can be used for synthesis of PROTAC BRD4 Degrader-31.

KLHDC2 ligand 1 is an E3 ligase ligand. KLHDC2 ligand 1 can be used for synthesis of PROTAC BRD4 Degrader-31.

S 16317 is an orally active dihydropyridine derivative with low calcium channel affinity (Ki: 0.55 μM). S 16317 inhibits P-gp mediated efflux of ADR. S 16317 overcomes multidrug resistance in tumor.

Mm-C3-OSu (Methyl Maleate-C3-N-Hydroxysuccinimide Ester) is a structurally defined linker intermediate with a cis-configured methyl maleate (Mm) core and a C3 alkyl chain terminated by an N-hydroxysuccinimide (OSu) reactive group, designed for constructing stable antibody-drug conjugates (ADCs).

Z1609609733 (Compound 18) is a non-covalent 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 1.46 μM. Z1609609733 significantly inhibits serine synthesis and cancer metabolism with complete abrogation of cell proliferation.

308-R-C4-PEG3-C1-Boc is a SGK3 ligand-linker conjugate that can be used for synthesis of PROTAC SGK3 degrader-2.

USP7 Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for USP7 and a PROTAC linker, which recruits E3 ligases. USP7 Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC USP7 Degrader-1.

tert-Butyl 6-bromohexanoate is a PROTAC linker. tert-Butyl 6-bromohexanoate can be used to design PROTAC, such as PROTAC ERK5 degrader-1.

LCB 2853 (sodium) is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist. LCB 2853 (sodium) exhibits anti-aggregant and anti-vasospastic effects. LCB 2853 (sodium) can be used for the research of cardiovascular disease, such as hypertension.

RBx-7796 (sodium) is a competitive, highly selective, orally active 5-LO (IC50 = 3.5 mM for human 5-LO enzyme) inhibitor. RBx-7796 (sodium) can effectively inhibit 5-LO activity and LTB4 release. RBx-7796 (sodium) can significantly inhibit airway inflammation and bronchial constriction.

PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC50 of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC50 values ​​of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia.

PD 155080 is a selective endothelin A receptor (ETA receptor) antagonist. PD 155080 reduces coronary resistance in the isolated rat heart model. PD 155080 improves myocardial systolic function and diastolic function in the ischemia/reperfusion model. PD 155080 can be used for the study of cardiovascular diseases.

Yoda2 (KC289) is the potassium salt of Yoda1. Yoda2 is an agonist of PIEZO1 with an EC50 of 150 nM. Yoda2 evokes Ca2+ elevation in HeLa cells. Yoda2 can cause concentration-dependent and NO-dependent relaxation in mouse portal vein (EC50 = 1.2 μM). Yoda2 can stimulate NOS3 and NO production.

E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections.

CKD-731 is a Fumagillin analogue. CKD-731 inhibits the proliferation of calf pulmonary artery endothelial cells (CPAE), lymphoma EL-4 cells and murine leukemia P388D1 cells. CKD-731 exerts the effect of inhibiting MetAP-2 activity and blocking angiogenesis. CKD-731 can be used for the research of anti-angiogenesis-related cancer.